Ping Zhang  Ping Zhang photo         

contact information

Research Staff Member, Master Inventor - Data Mining and Machine Learning
IBM T.J. Watson Research Center, Yorktown Heights, NY 10598, USA
  +1dash914dash945dash4498

links



AMIA 2015 Panel

Recent Advances in Computational Drug Repositioning

Panelists: Ping Zhang (IBM T.J. Watson Research Center), Atul Butte (University of California San Francisco), Nigam Shah (Stanford University), Nicholas Tatonetti (Columbia University), Hua Xu (The University of Texas Health Science Center at Houston)

Abstract:

Computational drug repositioning is a promising and efficient tool for discovering new uses from existing drugs and holds the great potential for precision medicine in the age of big data. The explosive growth of large-scale genomic and phenotypic data, as well data of small molecular compounds with granted regulatory approval, is enabling new developments for computational repositioning. To achieve the shortest path towards new drug indications, advanced data processing and analysis strategies are critical for making sense of these heterogeneous molecular measurements. Despite the progress simulated by big data analytics, there is clearly room for technical improvement with regard to computational drug repositioning methods. Furthermore, to materialize the true potential and impact of these methods, much work is needed to show that they can be successfully adopted into practical applications. In this panel, participants will summarize the recent advances in computational drug repositioning and identify challenges and opportunities. Panel participants will synthesize their perspectives on these key issues and likely future developments in this area, explore a diverse set of topics, and engage in thoughtful discussion with the audience.

 

AMIA Joint Summits 2017 Panel

Big Data for Pharmacovigilance: Challenge and Opportunity

Panelists: Ping Zhang (IBM T.J. Watson Research Center), Graciela Gonzalez (University of Pennsylvania), Rave Harpaz (Oracle Health Sciences), Ying Li (IBM T.J. Watson Research Center), Nigam Shah (Stanford University)

Abstract:

Adverse drug reactions (ADRs) are a major burden for patients and the healthcare industry. It usually causes preventable hospitalizations and deaths, while associated with a huge amount of cost. Spontaneous reporting systems (SRSs) have been the cornerstone in pharmacovigilance for a long time, and are effective at detecting many types of ADRs. However, significant under-reporting bias inherently leaves patients at risk until sufficient clinical evidence has been granted. To augment the current systems, there are new ways to conduct pharmacovigilance using expanded data sources including data from electronic health records (EHRs), scientific literature and social media. Collectively labeled as the big data, they share the characteristics of large volumes, diversity and complexity that present both challenges and opportunities to its holders. Recently, the research community has devoted much effort to this field that may fundamentally transfer the manner in which ADR can be identified and evaluated. However, there is clearly room for technical improvement with regard to computational drug safety surveillance methods. Furthermore, to materialize the true potential and impact of these methods, much work is needed to show that they can be successfully adopted into practical applications. In this panel, participants will summarize the recent advances in big data for pharmacovigilance and identify challenges and opportunities. Panel participants will synthesize their perspectives on these key issues and vision the future developments in this area, explore a diverse set of topics, and engage in thoughtful discussion with the audience.

 

AMIA Joint Summits 2018 Panel

Towards Large-scale Predictive Drug Safety: A Systems Pharmacology Perspective

Panelists: Ping Zhang (IBM T.J. Watson Research Center), Keith Burkhart (US FDA), Avi Ma'ayan (The Icahn School of Medicine at Mount Sinai), Lang Li (Ohio State University), Nicholas Tatonetti (Columbia University)

Abstract:

Adverse drug reaction (ADR) is a major burden for patients and healthcare industry. Systems pharmacology, which involves the application of systems biology approaches, combining large-scale experimental studies with computational analytics, can enhance the understanding of ADRs by looking at the effects of a drug in the context of cellular networks as well as exploring relationships between drugs. Recent efforts in high throughput experiments have generated a huge amount of data across the multiple biological scales of the organism, across a wide range of time scales, and across multiple species. These data sets provide unprecedented opportunities for systems pharmacology, but impose great challenges in big data management, mining, and integration. Furthermore, to materialize the true potential and impact of systems pharmacology approaches, much work is needed to show that they can be successfully adopted into practical applications. In this panel, participants will summarize the recent advances in informatics and systems pharmacology for drug safety and identify challenges and opportunities. Panel participants will synthesize their perspectives on these key issues and likely future developments in this area, explore a diverse set of topics, and engage in thoughtful discussion with the audience.